knowledge -WSS

knowledge

author：leisure time 2025-10-02 17:27:21 - browse：69555

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Kidney transplant patients stopped immunosuppressants in trial

hotspot

Wikipedia

WSS

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Lung cancer screening guidelines updated for cigarette smokers

Medicare proceeds with plan to claw back hospital funds

Inari Medical to buy amputation prevention company LimFlow

Think you might have Covid

New brain studies show LSD's effects on the brain in full color

focus

knowledge

hotspot

Bright Health sells Medicare Advantage business to Molina

Humans aren't the only ones with an imagination. Rats have it too

Tori Bowie and the unacceptable rates of Black maternal death

Medicare Advantage today, explained in one chart

As demand for Covid shots wanes, Moderna seeks its next success

Humans aren't the only ones with an imagination. Rats have it too

Medicare proposal to cover medical devices draws a mixed reaction

Prior authorization will have to move faster under new Biden rule

How to save PrEP access — and even expand it

My yearlong odyssey to get my son’s ADHD medication covered

focus

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Think you might have Covid

Parkinson’s finding may lead to tests and, someday, treatments

Kidney transplant patients stopped immunosuppressants in trial

Kidney transplant patients stopped immunosuppressants in trial

Gene therapy’s promise and the high cost of hope

hotspot

Wikipedia

leisure time

Wikipedia